Sanjiv Patel - Feb 7, 2023 Form 4 Insider Report for Relay Therapeutics, Inc. (RLAY)

Signature
/s/ Brian Adams, as Attorney-in-Fact
Stock symbol
RLAY
Transactions as of
Feb 7, 2023
Transactions value $
-$670,040
Form type
4
Date filed
2/9/2023, 04:09 PM
Previous filing
Jan 19, 2023
Next filing
Sep 29, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RLAY Common Stock Options Exercise $70.6K +14K $5.04 14K Feb 7, 2023 Direct F1
transaction RLAY Common Stock Sale -$300K -14K -100% $21.45 0 Feb 7, 2023 Direct F1, F2
transaction RLAY Common Stock Options Exercise $70.6K +14K $5.04 14K Feb 8, 2023 Direct F1
transaction RLAY Common Stock Sale -$294K -14K -100% $20.98 0 Feb 8, 2023 Direct F1, F3
transaction RLAY Common Stock Options Exercise $70.6K +14K $5.04 14K Feb 9, 2023 Direct F1
transaction RLAY Common Stock Sale -$288K -14K -100% $20.55 0 Feb 9, 2023 Direct F1, F4
holding RLAY Common Stock 675K Feb 7, 2023 By The Patel Family Irrevocable Trust of 2019 F5
holding RLAY Common Stock 687K Feb 7, 2023 By The SSP Irrevocable Trust of 2020 F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -14K -2.29% $0.00 597K Feb 7, 2023 Common Stock 14K $5.04 Direct F1, F6
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -14K -2.35% $0.00 583K Feb 8, 2023 Common Stock 14K $5.04 Direct F1, F6
transaction RLAY Stock Option (Right to Buy) Options Exercise $0 -14K -2.4% $0.00 569K Feb 9, 2023 Common Stock 14K $5.04 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 22, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $21.25 to $21.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 This transaction was executed in multiple trades at prices ranging from $20.73 to $21.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F4 This transaction was executed in multiple trades at prices ranging from $20.25 to $20.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F5 These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F6 The shares underlying this option shall vest in sixteen (16) equal quarterly installments after April 23, 2019, subject to the reporting person's continued employment through each applicable vesting date.